




A Cancer Service for the future at ENHT



Our virtual Annual General Meeting

Wednesday 15 July 2020

Overview



Highlights: delivering safe and timely cancer care



Highlights: developing and training our people

Schwartz Rounds – The day I made a difference

3D printer study day

Administering Chemotherapy for Jehovah Witness

Introduction to Cancer

Transforming treatment through Immuno-Oncology

Introduction to Radiotherapy

Updates on Chemotherapy (for nurses)

5 Priorities for care of the dying person

Quality


People

Pathways

Ease of use

Sustainability

Endoscopic Mucosal Resection of Polyps



Highlights: current advanced cancer treatments offered at ENHT



Robotic Surgery




Cyberknife treatment

Highlights: developing the future Mount Vernon Cancer Centre

Phase 1: identification of a tertiary cancer provider to provide clinical leadership to MVCC


Phase 2: development and evaluation of options for services




We are here



Providing cancer services safely during the COVID-19 pandemic



Future Opportunities to develop Cancer Care at ENHT



SPECT - CT

Future Opportunities to develop Cancer Care at ENHT





Asceptic production – making chemotherapy for our patients



Improving access to Radiotherapy

Introduction of PET-CT scanning at Lister



PET Scanner at Lister Hospital



Breakthrough Urinary Biomarker Bladder Cancer Research at ENHT



East and North Hertfordshire
IHS Trust



Mount Vernon Cancer Centre

1 February 2019 · 🌐

Following a competitive selection process, the Trust has been chosen by K Dx Diagnostics as the first European site to lead a study looking into whether K Dx's UroX Biomarker can help improve diagnosis and outcomes for patients with bladder cancer. A biomarker is a measurable indicator of the severity or presence of a disease.

Click on the link below to find out more.



ENHERTS-TR.NHS.UK

Trust selected as first European site for bladder cancer study | East and North Herts NHS Trust



Medical Device Safety Service

MDSS GmbH · Schiffgraben 41 · 30175 Hannover · Germany

K Dx Diagnostics, Inc.

Ms. Sholeh Jahanfard, President

575 W. Hacienda Avenue, Suite 316

Campbell, CA 95008

USA


+49 511 62628630

info@mdssar.com

www.mdssar.com

2020.06.16

Confirmation of CE Notification p108064



Quality

People




Pathways

Ease of use

Sustainability

URO17 Bladder Cancer – 150 patients data from ENHT

- CE – Marking Approved
- ENHT to first site to lead URO17 Biomarker introduction in Europe.
- Significant Benefit for Bladder Cancer patient diagnosis, treatment and follow up.
- Current data on 150 patients at ENHT
 - 100% Sensitivity and 93% Specificity in New Bladder Cancer patients *



Cytokine guided Robotic Urological Surgery

	Mean ± Standard Deviation		p value
	Pneumoperitoneal Pressure 12mmHg (n=5)	Pneumoperitoneal Pressure 15mmHg (n=5)	
Intraoperative Blood Loss (mL)	93 ± 69	56 ± 9	<0.05 (6.3x10 ⁻³⁶)
Length of Stay (Days)	1.6 ± 0.5	2 ± 0	0.910
Operative Time (minutes)	170 ± 14	165 ± 5	0.578
Console Time (minutes)	143 ± 19	140 ± 14	0.553
Postoperative Hb (g/L)	117.2 ± 6.4	120.4 ± 4.3	0.941
Postoperative Creatinine	87.6 ± 17.3	87.2 ± 4.4	0.076

- ENHT and UoH are leading Low Pressure Robotic Surgical Research using cytokines (World's first study)
- First paper published in June 2020
- Collaborations currently between
 - Belgium
 - USA
 - India



Supporting people to live with and beyond cancer - personalised cancer care

**CANCER
DOESN'T ALWAYS
STOP WHEN
TREATMENT
ENDS**

How can we ensure everyone gets the support they need to live well with and beyond cancer?



Quality

People

Pathways

Ease of use

Sustainability



Cancer Doesn't Stop for Coronavirus

Don't wait! Call your doctor today if you
have symptoms.

Quality

People

Pathways

Ease of use

Sustainability